As steadily increasing numbers of mRNA vaccines and therapeutics advance through clinical trials and commercialization, the biopharmaceutical industry is pressed to find ways to make their production ...
EnginZyme reports that it has patented a process to synthesize pseudouridine, a key ingredient in mRNA COVID-19 vaccines. The company and its CDMO partner, Ajinomoto Bio-Pharma Services, say they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback